Executive Officers
- James A. Joyce - Chairman and CEO
James A. Joyce founded Aethlon Medical in May 1998, and presently serves as Chairman, President and Chief Executive Officer. During Mr. Joyce's tenure, Aethlon has evolved the concept of a medical device to treat infectious disease into a reality of treating infected patients in a clinical trial environment. The resulting Hemopurifier® technology is positioned to treat global pandemic issues such as HIV/AIDS, Hepatitis-C, H5N1 Avian Flu, and pathogens most likely to be weaponized for use in bioterrorism. Mr. Joyce has been an active participant in the emerging biodefense industry. He has testified before Congress on issues related to Project BioShield legislation and the deployment of the Hemopurifier® as a countermeasure against biological weapons. His efforts have been instrumental in expanding the definition of treatment countermeasure in Project BioShield legislation to include medical devices. Mr. Joyce recently served on the Project BioShield panel at the Federal Biodefense Research Conference, the Biodefense panel at the 2006 Homeland and Global Security Summit, and was named Co-Chairman of the Bioterrorism/Chemical and Nuclear Security Task Force of the Homeland Security Industries Association. Mr. Joyce actively discusses issues related to infectious disease at various conferences, and has been interviewed in related news stories on CNN, NBC, ABC, the BBC, and other media outlets. From February 1993 until founding Aethlon Medical, Mr. Joyce owned James Joyce & Associates, a senior management advisory organization. Previously, he was founder and Chief Executive Officer of Mission Labs, Inc., was a principal at London Zurich Securities, Inc., and was a member of the Denver Broncos of the National Football League. Mr. Joyce is a graduate of the University of Maryland.
x - Jim Frakes - Senior Vice President, Finance
Mr. Frakes joined Aethlon Medical in January 2008 and brought 16 consecutive years of financial responsibility for publicly traded companies, as well as, specific knowledge and experience in equity and debt transactions, acquisitions, public reporting and Sarbanes-Oxley section 404 internal control requirements. He also serves as the CFO for Left Behind Games Inc., a start-up video game company. Prior to 2006, he served as CFO of NTN Buzztime, Inc., an interactive entertainment company with $40 million in sales, where he played a key role in acquisitions that doubled the company's revenue. Additionally, he was involved in the IPO and subsequent private placements. From 1997 to 2001 he was CFO of Play Co. Toys/Toys International, a company that required managing the turnaround process to convert a regional chain of toy stores to a national chain, a process that entailed two public stock offerings, a private placement and the arrangement of credit facilities aggregating $25 million. His first CFO appointment was with Urethane Technologies, Inc., again, a situation that entailed public stock offerings, private placements and the establishment of debt facilities.
Since early 2007 Mr. Frakes has been a member of the San Diego practice of Tatum, LLC, the nation's largest executive services firm where he continues an association. His earliest career experience was in investment banking at Berkeley International Capital Corp., Lloyds Bank International Ltd., and Security Pacific National Bank.
Mr. Frakes received an MBA from the University of Southern California, and did his undergraduate work at Stanford University.
x - Richard H. Tullis, Ph.D. - Vice President, Chief Science Officer
Dr. Tullis has extensive biotechnology management and research experience, and is the founder of Syngen Research, a wholly-owned subsidiary of Aethlon Medical, Inc. Dr. Tullis became a Vice President and Director of Aethlon Medical, Inc. in January of 2000, and succeeded Dr. Clara M. Ambrus as Chief Scientific Officer in June of 2001. Previously, Dr. Tullis co-founded Molecular Biosystems, Inc., a former NYSE company. At Molecular Biosystems, Dr. Tullis was Director of Research and Development, Director of Oligonucleotide Hybridization, Senior Research Scientist and Member of the Board of Directors. In research, Dr. Tullis developed and patented the first application of oligonucleotides to antisense antibiotics and developed new methods for the chemical synthesis of DNA via methoxy-phosphorochloridites. Dr. Tullis also co-developed the first applications of covalently coupled DNA-enzyme conjugates using synthetic oligonucleotides during his tenure at Molecular Biosystems. In 1985, Dr. Tullis founded, and served as President and CEO of Synthetic Genetics, Inc., a pioneer in custom DNA synthesis, which was sold to Molecular Biology Resources in 1991. Dr. Tullis also served as interim-CEO of Genetic Vectors, Inc., which completed its IPO under his management, and was co-founder of DNA Sciences, Inc., a company that was eventually acquired by Genetic Vectors. Dr Tullis received his Ph.D. in Biochemistry and Cell Biology from the University of California at San Diego, and has done extensive post-doctoral work at UCSD, USC, and The Scripps Research Institute.
x - Jeff Richardson - Senior Director, Communications
Mr. Richardson has nearly 20 years of senior leadership in global public relations for research-based medical companies. Prior to joining Aethlon, Mr. Richardson was Director, Global Public Relations for Amgen, the world's largest biotechnology company. Previously, he held senior communications positions with both Glaxo and DuPont. Mr. Richardson is responsible for establishing government and military communication initiatives and manages medical industry and investor relations programs.
x